Eikon Therapeutics, a pivotal-stage biotechnology company that integrates engineering with molecular and cell biology to accelerate drug discovery and development, has raised over $350 million in a series D funding round led by an investment syndicate composed of mutual funds, sovereign wealth funds, and healthcare and technology-focused venture firms.

Eikon Therapeutics plans to allocate the funds raised to advance its clinical-stage programs and expand its future pipeline. The funding will support the development of Eikon’s lead programme, EIK1001, a systemically administered co-agonist of toll-like receptors 7 and 8, currently in a Phase III trial for advanced melanoma. Additionally, the capital will facilitate the progression of EIK1003, a highly selective PARP1 inhibitor undergoing Phase I evaluation for various cancers, and EIK1004, a central nervous system-penetrant PARP1-selective inhibitor poised to initiate Phase I studies targeting brain cancers.